Veri MedTech IPO Amendment Reveals Going Concern, Material Weakness, and $15M Raise Terms
VRHID has more than doubled off its 52-week low of $0.335.
Summary
Veri MedTech's IPO amendment finalizes $15M raise terms at $4.00/share while disclosing going concern doubt, a material weakness, and only $6,146 in cash. Management states $2 million is needed to survive the next year. NASDAQ listing approval is a condition to closing.
Updated with an SEC S-1/A filing · What changed
Updates
· SEC S-1/A — Management states $2 million is needed to survive the next year.
Key Events · Financing and Capital Events · VRHID
-
Updated · · SEC S-1/A
Going Concern Warning and Funding Need
Auditors and management state substantial doubt about the company's ability to continue as a going concern; working capital deficit of $2.46M and only $6,146 in cash as of June 30, 2026. Management states $2 million is needed to survive the next year.
-
IPO Terms Finalized at $4.00/Share
3,750,000 shares at $4.00 per share for $15M gross proceeds; net proceeds approximately $11.95M after 7% underwriting discount, 2% corporate finance fee, and $1.70M offering expenses.
-
Material Weakness in Financial Staffing
Company discloses a material weakness relating to financial staffing and plans to use up to $200,000 of IPO proceeds to strengthen its finance and accounting function.
-
Underwriter Compensation and Warrants
Network 1 Financial receives 7% discount, 2% corporate finance fee, $150,000 accountable expense reimbursement, and warrants for 5% of shares sold (187,500 shares) at $4.80 exercise price.
Analysis · VRHID · Technology
The seventh S-1 amendment from Veri MedTech finalizes the terms of its $15 million IPO at $4.00 per share, but it also discloses substantial doubt about the company's ability to continue as a going concern, a material weakness in financial staffing, and a working capital deficit of $2.46 million. Management states $2 million is needed to survive the next year. The offering is contingent on NASDAQ Capital Market approval, and the company has only $6,146 in cash as of June 30, 2026. The underwriter compensation package includes 7% discounts, a 2% corporate finance fee, and warrants for 5% of shares sold at $4.80. The company's executives retain 80% voting control through Series A Preferred Stock, and a 1-for-2.5 reverse split was completed September 2, 2026.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 966 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.66%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VRHID was trading at $5.00 on OTC in the Technology sector, with a market capitalization of approximately $40M. The 52-week trading range was $0.34 to $6.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.